Proliferative myositis of the latissimus dorsi presenting in a 20-year-old male athlete.
Neil McHugh(University of Bath), Jason Kelly(Cork University Hospital), Michael Bennett(Cork University Hospital), James Larkin(Trinity College Dublin), David Ryan(University College Cork), Fiachra Moloney(Cork University Hospital), Caitlin Beggan(Cork University Hospital), Ruth Tevlin(Washington University in St. Louis)
PubMed
August 8, 2017
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k